GDm-Health is a digital therapeutic to help mothers-to-be, and their clinical care teams, remotely manage diabetes during pregnancy - comprising a smartphone application connected to a wireless blood glucose monitor. The traditional method of manually recording glucose levels on paper by women is time-consuming, open to the risk of transcription errors, and does not allow clinicians to review real-time changes in symptoms to prioritise women at need.At present GDm-Health is live in 16 Trusts with a further 4 Trusts going live in the next few months.
GDm-Health began as a collaboration between Oxford University Hospitals NHS Foundation Trust and the University of Oxford’s Institute of Biomedical Engineering. The system was invented, and clinical development led, by Dr Lucy Mackillop, a consultant obstetric physician at Oxford University Hospitals NHS Foundation Trust, Honorary Senior Clinical Lecturer in women’s and reproductive health at the University of Oxford, and VP of Medical Affairs at Sensyne Health.
Since its launch in August 2018 GDm-Health has helped mothers-to-be avoid an estimated 1,312 caesarean sections, 532 pre-term births, with 780 mothers avoiding transitioning to pharmacological treatment[LM1] [JC2]. Using GDm-Health has also been associated with potential for cost-savings to the NHS with a 26% reduction in the number of clinic visits and 50% less time spent on clerical and administrative tasks by midwives. According to an independent NICE review, this is estimated at £230 per woman per pregnancy of cost savings.
“GDm-Health has made a tangible difference to the lives of women during pregnancy. We are very pleased with the rapid uptake of GDm-Health by NHS Trusts, and thrilled by the recognition of this HSJ award. With GDM becoming more prevalent, it is vital that the latest technological insights available be utilised to help women and their clinicians better manage this condition.”
Dr Lucy Mackillop, clinical lead for the development of GDm-Health
GDm-Health was designed with significant input from patients, to ensure it is easy to use: 92% of women using GDm-Health report a high user satisfaction, and 98% of users would recommend to family and friends. These factors likely contributed to a31% improvement in blood glucose monitoring compliance by users of the system compared to paper recording.
In February 2020, Sensyne Health was awarded an HSJ Partnership Award for its GDm-Health product in the ‘Medtech, Device or Hardware Innovation’ category. The award recognised the close partnership between Sensyne and the Oxford University Hospitals NHS Foundation Trust.
- Development of a Real-Time Smartphone Solution for the Management of Women With or at High Risk of Gestational Diabetes; J Diabetes Sci Technol 2014vol. 8 no.
- Estimates calculated in October 2019 using statistics generated in a Randomised Control Trial. Please see: Comparing the Efficacy of a Mobile Phone-Based Blood Glucose Management System With Standard Clinic Care in WomenWith Gestational Diabetes: Randomized Controlled Trial; Mackillop et al; JMIRMhealth Uhealth. 2018 Mar 20;6(3):e71 (www.ncbi.nlm.nih.gov/pubmed/29559428)